NHS in England Approves Life-Extending Breast Cancer Drug Enhertu Following Years of Campaigning

Women living with an incurable form of breast cancer in England have been granted access to a life-extending medication on the National Health Service, reversing a controversial ruling made two years ago that had deemed the treatment unaffordable.

The pharmaceutical therapy, known as Enhertu, has been shown to prolong patient survival by an average of roughly seven months, with certain individuals gaining up to three additional years of life. The regulatory shift is expected to benefit approximately 1,000 women each year diagnosed with HER2-low metastatic breast cancer.

Medical practitioners across England were authorized to begin prescribing the treatment on Thursday. While Wales is projected to follow suit in the near future, the newly updated clinical guidance will not automatically extend to Northern Ireland. In contrast, patients in Scotland have had subsidized NHS access to Enhertu since 2023, while women across 26 other European nations have also been able to receive it.

The availability of the drug in England follows extensive advocacy from patients and healthcare charities. Campaigners had persistently pushed for wider distribution after the National Institute for Health and Care Excellence (NICE) ruled in 2024 that the medication did not represent sufficient value for money.

Welcoming the revised guidance, Health Secretary Yvette Cooper described Enhertu as potentially life-changing for patients who will now finally be able to benefit through the public health system. She praised the resolve of patient advocates and charitable organizations who worked tirelessly to challenge the original ruling.

However, the announcement has prompted mixed feelings among healthcare advocates. Claire Rowney, the chief executive of the charity Breast Cancer Now, acknowledged the milestone while lamenting the extensive delays that prevented thousands of terminally ill patients from accessing the treatment before they died.

Rowney emphasized that while campaigners could celebrate their hard-fought success, the substantial human toll of the regulatory impasse could not be overlooked. She urged the government, NHS England, NICE, and pharmaceutical firms to collaboratively reform the appraisal framework so patients with advanced cancer are not forced to spend their remaining time lobbying for access to life-extending treatments.

Among those directly affected by the decision is 51-year-old Kate Wills, who is living with HER2-low metastatic breast cancer that has migrated to her lungs and bones. Despite balancing a demanding professional career, family life, and ongoing treatment, she previously described the inability to obtain Enhertu on the NHS as deeply distressing.

Upon learning that the medication would finally be covered, Wills expressed profound emotional relief. Having previously focused on surviving long enough to see her youngest child complete school, she explained that the new treatment option has allowed her to hope for future milestones, such as watching her son and daughter fall in love and marry.

Even so, Wills noted that the victory remains bittersweet because several of her peers succumbed to the disease while waiting for the drug to be approved. Among them was Jeannie Ambrose, who campaigned publicly for access two years ago at the age of 53, insisting she wanted to spend her final months enjoying time with loved ones rather than fighting health authorities. Ambrose died in January.

The reversal by NICE was not driven by significant price cuts from the pharmaceutical developers, Daiichi Sankyo and AstraZeneca, who maintained their pricing structure. Instead, the breakthrough was largely facilitated by an international trade agreement between the United Kingdom and the United States, under which the UK pledged to boost its overall spending on pharmaceuticals by 25 percent.

As a consequence of that broader economic agreement, NICE adjusted its valuation parameters for novel therapies. The upper limit for a Quality-Adjusted Life Year (QALY)—the metric used to calculate the cost-effectiveness of extending a patient's life in good health—was raised from £30,000 to £35,000.

In addition to raising the QALY spending ceiling, NICE implemented an updated and more nuanced framework for evaluating patient quality of life at the end of August. These combined analytical changes provided the necessary administrative justification to reverse the earlier rejection of Enhertu.

Both Daiichi Sankyo and AstraZeneca welcomed the updated recommendation from NICE. AstraZeneca emphasized the importance of fostering deeper cross-sector collaboration throughout the healthcare network to ensure that innovative treatments reach patients across the country more quickly and equitably in the future.

Helen Knight, the director of medicines evaluation at NICE, expressed satisfaction that a workable commercial resolution had been reached, bringing closure to a prolonged dispute and unlocking a critical line of treatment for advanced breast cancer patients.